Comparing low and standard dose-intensity continuous renal replacement therapy in critically ill patients
Official title: LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM): A Pilot Randomized Trial
Run by University of Alberta · NCT06446739 · Data updated 2026-11-12
This study is testing if a lower dose of kidney treatment is just as good as the standard dose for critically ill patients with acute kidney injury.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University of Alberta Academic / other |
| Locations | 10 sites (Rochester, Minnesota and 9 other locations) |
| Status | Recruiting |
| Started | November 14, 2024 |
| Main results expected | December 2026 |
| Study ends | June 2027 |
| Registry record updated | October 28, 2026 |
| Trial ID | NCT06446739 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are critically ill adults aged 18 years and older who are expected to receive continuous renal replacement therapy for acute kidney injury.
✕Probably not a fit
Patients with end-stage kidney disease requiring maintenance dialysis or those needing higher dose-intensity CRRT will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The WISDOM trial aims to evaluate whether a lower dose-intensity of continuous renal replacement therapy (CRRT) is as effective as the standard dose-intensity for critically ill patients suffering from acute kidney injury (AKI). This interventional study will compare the outcomes of patients receiving lower dose-intensity CRRT against those receiving the standard guideline-directed dose. The primary goal is to determine if the lower dose is non-inferior in terms of CRRT duration and kidney recovery. Additionally, the study will assess if the lower dose can lead to shorter CRRT duration and improved recovery outcomes. This trial is significant as it addresses a gap in current clinical guidelines regarding the minimum effective dose of CRRT.
Why it matters
Potential benefit: If successful, this study could lead to more cost-effective and less invasive treatment options for critically ill patients with acute kidney injury.
How similar studies have gone: While previous studies have explored CRRT dose-intensity, this trial is novel as it specifically investigates the lower dose-intensity threshold, which has not been previously evaluated in randomized controlled trials.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age ≥ 18 years * weight ≥ 55 kg * plan to initiate CRRT or within 24 hours of having started CRRT for AKI * expected to survive and receive CRRT for a duration of ≥ 48 hours * able to provide informed consent or have an authorized representative provide consent after being informed on the details and risks of the trial unless a deferred consent process is approved by local Research Ethics Board (REB). Exclusion Criteria: * indication for sustained higher dose-intensity CRRT as designated by the attending clinicians * end-stage kidney disease receiving maintenance dialysis * receipt of any RRT for AKI during the current hospitalization * inability to comply with the requirements of the study protocol.
Where it's running
-
Mayo Clinic
Rochester, Minnesota, United States Recruiting -
Foothills Medical Centre
Calgary, Alberta, Canada Recruiting -
University of Alberta Hospital
Edmonton, Alberta, Canada Recruiting -
Grey Nuns Hospital
Edmonton, Alberta, Canada Recruiting -
Sturgeon Community Hospital
St. Albert, Alberta, Canada Recruiting -
Hamilton General Hospital
Hamilton, Ontario, Canada Recruiting
Show 4 more locations
-
Sunnybrook Health Sciences Centre
North York, Ontario, Canada Recruiting -
St Michael's Hospital
Toronto, Ontario, Canada Recruiting -
Regina General Hospital/Saskatchewan Health Authority
Regina, Saskatchewan, Canada Recruiting -
Guy's & St Thomas' Hospitals
London, United Kingdom Recruiting
Study contacts
- Principal investigator: Sean M Bagshaw, MD — University of Alberta
- Study coordinator: Sean M Bagshaw, MD
- Email: bagshaw@ualberta.ca
- Phone: 780-248-1256
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Epidemiology and care for dialysis in ICU patients with severe acute kidney injury in Latin America
This project will collect and compare data on adults in ICUs across Latin America who need dialysis for severe acute kidney injury to see how they are treated and what outcomes they have.
-
Choosing Wisely recommendations for care in the intensive care unit
This project will try the Choosing Wisely approach in adult ICU patients in Sweden to see if using fewer unnecessary tests and interventions is safe.
-
Timing of kidney treatment in critically ill patients
This study is trying to find out if starting kidney treatment earlier can help critically ill patients with kidney injury feel better and have better outcomes.
-
Italian Registry of Pediatric Dialysis: collecting data from kids on kidney replacement therapy
This registry in Italy tests how collecting epidemiological, clinical, and treatment data from children on dialysis or pre-emptive kidney transplants can help centers share protocols and improve care.
-
3D Ultrasound Support for Hemodialysis Cannulation
This study tests whether the EchoMap device can help safely cannulate an arm fistula during hemodialysis for adults.
-
Remote Ischemic Preconditioning at Different Times After Heart Valve Surgery
This study tests whether applying brief, controlled blood-flow restrictions to a limb at different times after heart valve surgery can help protect organs and reduce complications like kidney injury.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.